Latest Funding And Investment News

Perennial Investment Management Limited has announced an estimated monthly distribution of 1.785 cents per unit for January 2025 for the Perennial Income Generator Fund (ASX: EIGA), outlining key dates and options for unitholders.

Renegade Exploration has revealed significant concentrations of critical defence metals germanium and gallium at its Andrew Deposit in Yukon, Canada, highlighting new strategic value in its zinc-lead-silver project. The discovery aligns with increased government interest in critical minerals infrastructure.

A1 Investments & Resources Ltd reported a modest cash outflow for the December quarter while actively pursuing acquisition opportunities backed by secured funding. The company aims to finalize a deal soon, contingent on shareholder and regulatory approvals.

Betashares Capital Ltd has announced a final distribution of 8.02 cents per unit for its Western Asset Australian Bond Active ETF for January 2025, outlining key dates and reinvestment options for investors.

Following a recent unitholder meeting, One Managed Investment Funds Limited has initiated the orderly liquidation of the Fat Prophets Global Property Fund’s portfolio, signaling a significant transition for investors.

Sunshine Metals Limited reported a $179,000 net cash outflow from operating activities in the December 2024 quarter, with cash reserves standing at $1.5 million. The company is actively exploring funding options to sustain its exploration programs amid fluctuating cash flows.

Castle Minerals Limited reports promising drilling results at its Wa Gold Project and secures a transformative $3 million investment from Ghana's Minerals Income Investment Fund for its Kambale Graphite Project.

Redivium's Q2 FY25 report reveals strategic progress in lithium-ion battery recycling across Europe, including new partnerships and feasibility studies, while navigating tight cash reserves and a critical entitlement offer.

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.